
|Articles|October 1, 2003
Clinical Trials Successful
Auckland, New Zealand - Intradermal injection of a purified cell wall component from heat-killed Mycobacterium vaccae may one day be used to treat children with severe atopic dermatitis, if a clinical program carried out by a New Zealand company continues to be successful.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
AbbVie Files for Vitiligo Indication, Putting Systemic Therapy Under Regulatory Review
2
Icotrokinra Shows Superior Efficacy Over Advanced Oral Therapies in New Psoriasis Meta-Analysis
3
Nutrafol Expands Portfolio with First and Only Hair Loss Supplement for Male Patients 50 and Older
4
Introducing Dermatology Times NP/PA Connect
5











